1
|
Yang H, Yu H, Stolarzewicz IA, Tang W. Enantioselective Transformations in the Synthesis of Therapeutic Agents. Chem Rev 2023; 123:9397-9446. [PMID: 37417731 DOI: 10.1021/acs.chemrev.3c00010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/08/2023]
Abstract
The proportion of approved chiral drugs and drug candidates under medical studies has surged dramatically over the past two decades. As a consequence, the efficient synthesis of enantiopure pharmaceuticals or their synthetic intermediates poses a profound challenge to medicinal and process chemists. The significant advancement in asymmetric catalysis has provided an effective and reliable solution to this challenge. The successful application of transition metal catalysis, organocatalysis, and biocatalysis to the medicinal and pharmaceutical industries has promoted drug discovery by efficient and precise preparation of enantio-enriched therapeutic agents, and facilitated the industrial production of active pharmaceutical ingredient in an economic and environmentally friendly fashion. The present review summarizes the most recent applications (2008-2022) of asymmetric catalysis in the pharmaceutical industry ranging from process scales to pilot and industrial levels. It also showcases the latest achievements and trends in the asymmetric synthesis of therapeutic agents with state of the art technologies of asymmetric catalysis.
Collapse
Affiliation(s)
- He Yang
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Hanxiao Yu
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Izabela A Stolarzewicz
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Wenjun Tang
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
- School of Chemistry and Material Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China
| |
Collapse
|
2
|
Feng Y, Zhou Z, Wu S, Lin W, Lu S, Pang X, Xia K, He F, Zhang Q, Yang H, Wang Z. Biocatalytic Asymmetric Reduction of a Sterically Hindered α-Bromo Ketone for the Synthesis of Key Intermediates of Olodaterol. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2023]
Affiliation(s)
- Yahui Feng
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Zihong Zhou
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510640, P. R. China
| | - Shuming Wu
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Wei Lin
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Songquan Lu
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Xiaolei Pang
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Ke Xia
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Fang He
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Qin Zhang
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
- College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, P. R. China
| | - Hu Yang
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Zhongqing Wang
- School of Pharmacy, Xiangnan University, Chenzhou 423000, Hunan, China
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| |
Collapse
|
3
|
Tang J, Chen L, Zhang L, Ni G, Yu J, Wang H, Zhang F, Yuan S, Feng M, Chen S. Structure-guided evolution of a ketoreductase for efficient and stereoselective bioreduction of bulky α-amino β-keto esters. Catal Sci Technol 2021. [DOI: 10.1039/d1cy01032h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Chiral vicinal amino alcohols were generated with excellent stereoselectivity and high conversion from bulky α-amino β-keto esters by an engineered ketoreductase called M30.
Collapse
Affiliation(s)
- Jiawei Tang
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China
| | - Liuqing Chen
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China
| | - Luwen Zhang
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Pudong, Shanghai 201203, P. R. China
| | - Guowei Ni
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Pudong, Shanghai 201203, P. R. China
| | - Jun Yu
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Pudong, Shanghai 201203, P. R. China
| | - Hongyi Wang
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Pudong, Shanghai 201203, P. R. China
| | - Fuli Zhang
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Pudong, Shanghai 201203, P. R. China
| | - Shuguang Yuan
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China
| | - Meiqing Feng
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, P. R. China
| | - Shaoxin Chen
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Pudong, Shanghai 201203, P. R. China
| |
Collapse
|